Top MHRA Official Emphasizes Patient Safety in Clinical Trials
The MHRA Chief Executive provides an update to staff on the Pathways clinical trial, reiterating the agency's commitment to ensuring the safety and well-being of trial participants.
MHRA, the UK's Medicines and Healthcare products Regulatory Agency, has always placed the safety and wellbeing of clinical trial participants at the forefront of its priorities. This was the core message conveyed by the MHRA Chief Executive in a recent update to the agency's staff regarding the ongoing Pathways clinical trial.
The Pathways trial, which is currently underway, is being closely monitored by the MHRA to ensure that the highest standards of safety and ethics are being maintained. As the regulatory body responsible for overseeing the development and approval of new medicines and medical devices in the UK, the MHRA takes its role in safeguarding trial participants extremely seriously.
{{IMAGE_PLACEHOLDER}}Source: UK Government
